IOVA

Iovance Biotherapeutics (IOVA)

About Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Details

Daily high

$7.44

Daily low

$7.07

Price at open

$7.17

52 Week High

$18.33

52 Week Low

$6.70

Market cap

2.2B

Dividend yield

0.00%

Volume

11.2M

Avg. volume

5.6M

P/E ratio

-4.93

Iovance Biotherapeutics News